Sickle Cell Anemia Update: Gene Therapy Reverses Pain Events for Years
An update on the investigational gene therapy LentiGlobin for sickle cell disease and research on complications and outcomes of this disorder.
An update on the investigational gene therapy LentiGlobin for sickle cell disease and research on complications and outcomes of this disorder.
Researchers sought to determine what the impact and challenges of the opioid crisis were on pain treatments for patients with sickle cell disease.
Researchers sought to determine what should be the primary treatment goal for patients with sickle cell disease.
Patients with kidney failure who receive a kidney transplant, including those with sickle cell disease, have lower mortality.
For patients with sickle cell disease, HSCT may not be associated with a significant increase in CKD incidence or prevalence following transplantation.
Increases in capillary density, functional exchange surface seen in microvasculature of skeletal muscle.
Fewer individuals in voxelotor group versus placebo group have worsened anemia at week 24.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
A multidisciplinary intervention strategy led to a 61% decrease in hospital stay duration for patients with sickle cell disease and vaso-occlusive pain.
Children born with sickle cell disease in low-resource regions of the world often remain undiagnosed and therefore do not receive appropriate treatment.